Home
Conditions
Carcinoma, Neuroendocrine

Clinical trial condition

Carcinoma, Neuroendocrine

Explore clinical trials studying Carcinoma, Neuroendocrine. Study availability and eligibility vary by location and protocol.

112 public trials 35 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Neuroendocrine trial results

Active, not recruiting

A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

NCT04524208

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +8 more
Locations: Medizinische Universität Wien Vienna, Austria

University Medical Center Göttingen Göttingen, Lower Saxony, Germany

Zentralklinik Bad Berka GmbH Bad Berka, Germany

Universitätsklinikum Carl Gustav Carus Dresden, Germany

View all 15 locations

View Trial Details

Completed

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

NCT03728361

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +27 more
Locations: Ohio State University Comprehensive Cancer Center-COHORT 1 Columbus, Ohio, United States

Ohio State University Comprehensive Cancer Center-COHORT 2 Columbus, Ohio, United States

View Trial Details

Completed

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

NCT05262556

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +12 more
Locations: University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

NCT00113360

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Islet Cell, +17 more
Locations: UT MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT01642251

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +23 more
Locations: Loma Linda University Medical Center Loma Linda, California, United States

Stanford Cancer Institute Palo Alto Palo Alto, California, United States

Rocky Mountain Cancer Centers-Aurora Aurora, Colorado, United States

The Medical Center of Aurora Aurora, Colorado, United States

View all 428 locations

View Trial Details

Completed

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430

Conditions: Adenocarcinoma, Adenoma, Adnexal Diseases, +139 more
Locations: xCures Oakland, California, United States

View Trial Details

Completed

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

NCT04069299

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +8 more
Locations: H Lee Moffitt Cancer & Research Institute Tampa, Florida, United States

View Trial Details

Completed

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

NCT03290079

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +9 more
Locations: H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States

View Trial Details

Completed

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

NCT02820857

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +8 more
Locations: Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens Amiens, France

Service d'Hépatogastroentérologie, CHU d'Angers Angers, France

Service d'Oncologie et Radiothérapie, Institut Sainte Catherine Avignon, France

Service de Gastroentérologie et Oncologie Digestive, Hôpital Avicenne Bobigny, France

View all 26 locations

View Trial Details

Completed

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

NCT01879657

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +8 more
Locations: Radio- Isotope Therapy of America Houston, Texas, United States

View Trial Details

Carcinoma, Neuroendocrine

Carcinoma, Neuroendocrine trial results

Related conditions